NEW YORK, August 3, 2016 /PRNewswire/ --
Stock-Callers.com focus is on the Biotech arena which has had an impressive performance in the last few days. On Monday, August 01, 2016, stocks within the biotech space drove the NYSE Arca Biotechnology Index up by 2.4%. Today, we review Arena Pharmaceuticals Inc. (NASDAQ: ARNA), BIND Therapeutics Inc. (NASDAQ: BIND), Nektar Therapeutics (NASDAQ: NKTR), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). Today's research reports on the aforementioned stocks are downloadable for free upon registration at:
San Diego, California-based Arena Pharmaceuticals Inc.'s shares fell 3.26%, finishing the session at $1.63. A total volume of 1.01 million shares was traded. Over the previous three months, the stock has advanced 0.62%. The Company's shares are trading below their 50-day moving average by 7.61%. Additionally, shares of Arena Pharma, which discovers, develops, and commercializes novel drugs that target G protein-coupled receptors to address unmet medical needs in the United States and South Korea, have a Relative Strength Index (RSI) of 42.79.
On July 19th, 2016, Eisai Inc. and Arena Pharma announced that the U.S. Food and Drug Administration has approved the New Drug Application for BELVIQ XR® (lorcaserin HCl) CIV extended-release 20 mg tablets. The new formulation of lorcaserin will offer patients a once-a-day dosing option that may help them achieve and maintain weight loss. BELVIQ XR is expected to be available in the fall of 2016. In connection with the approval, Arena Pharma will receive a $10 million milestone payment. Visit us today and access our complete research report on ARNA at:
On its last trading session (July 29, 2016), shares in Cambridge, Massachusetts headquartered BIND Therapeutics Inc. ended the session flat at $0.78. The stock recorded a three months average volume of 1.19 million shares. The Company's shares have surged 100.00% in the last month. The stock is trading above its 50-day moving average by 57.58%. Moreover, shares of BIND Therapeutics, which develops novel targeted therapeutics primarily for the treatment of cancer in the United States and Russia, have an RSI of 62.45.
On July 27th, 2016, BIND Therapeutics, announced that Pfizer Inc. prevailed at a Section 363 auction to purchase substantially all of BIND's assets in a $40 million bid. BIND initiated voluntary Chapter 11 bankruptcy protection on May 1st, 2016 and conducted a sale of assets, pursuant to Section 363 of the Bankruptcy Code, during an auction held on July 25th and 26th, 2016. The complimentary report on BIND can be downloaded at:
San Francisco, California headquartered Nektar Therapeutics' stock fell 3.27%, to close the day at $17.18. A total volume of 1.57 million shares was traded, which was above their three months average volume of 977,910 shares. The Company's shares have advanced 19.31% in the last one month, 10.20% in the previous three months, and 1.96% on an YTD basis. The stock is trading 13.25% and 21.56% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Nektar Therapeutics, which develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States, have an RSI of 65.32.
On July 27th, 2016, Nektar Therapeutics announced that it will release its financial results for the second quarter ended June 30, 2016, on August 3rd, 2016, after the close of the US markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time (ET) on the same day. Register for free on Stock-Callers.com and access the latest research report on NKTR at:
Shares in Tarrytown, New York headquartered Regeneron Pharmaceuticals Inc. recorded a trading volume of 1.25 million shares, which was above their three months average volume of 906,120 shares. The stock ended the session at $434.90, climbing 0.21%. The Company's shares have gained 21.31% in the past month and 17.12% in the previous three months. The stock is trading above its 50-day moving average by 14.82%. Furthermore, shares of Regeneron Pharmaceuticals, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide, have an RSI of 74.94.
On August 1st, 2016, Sanofi and Regeneron Pharmaceuticals announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for sarilumab, an investigational human monoclonal antibody directed against the IL-6 receptor that is intended for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). The MAA for sarilumab is primarily based on results from seven Phase 3 trials in the global SARIL-RA clinical development program, including SARIL-RA-MOBILITY, SARIL-RA-TARGET and SARIL-RA-MONAR. Get free access to your research report on REGN at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA